Laboratory study demonstrates enzymatic hydrolysis and yeast fermentation enrich protein 2.1-fold in alfalfa biomass, indicating a viable strategy for agricultural waste valorization.
Alfalfa biomass contains significant carbohydrate fractions underutilized in animal feed. This research optimized the enzymatic hydrolysis of Alfalfa biomass and evaluated single-cell protein (SCP) production using Candida utilis and Komagataella pastoris . Hydrolysis kinetics in this study showed biphasic sugar release, with enzymatic optimization increasing monomeric sugar yield from 18.5% to a maximum of 33.0% (a 78% relative increase) at 22 mg protein/g biomass enzyme loading. C. utilis demonstrated superior metabolic versatility, consuming 23% more total sugars than K. pastoris , with particularly enhanced pentose utilization showing 45% greater xylose consumption. K. pastoris achieved 51% faster growth rates than C. utilis , while both yeasts produced comparable protein yields per unit sugar consumed. SCP production enriched protein content 2.1-fold compared to raw Alfalfa biomass, reaching approximately 40% crude protein. Essential amino acid profiling (tryptophan excluded) showed that fermentation substantially improved several essential amino acids relative to FAO/WHO reference values, particularly lysine, threonine, and methionine; however, methionine + cysteine remained below the FAO reference ratio in both yeasts ( K. pastoris : 0.99; C. utilis : 0.87), indicating that sulfur-containing amino acids remain a limiting factor despite overall nutritional improvement. The integrated bioprocess achieved 27.6% carbohydrate-to-biomass conversion efficiency and 11.3% carbohydrate-to-protein conversion efficiency based on measured monomeric sugars (oligosaccharide utilization during fermentation was not independently quantified). This work demonstrates a promising lab-scale strategy for alfalfa valorization through enzymatic hydrolysis and yeast fermentation, yielding a nutritionally improved protein product; techno-economic analysis, feeding trials, and scale-up studies are required before cost-effectiveness or industrial readiness can be established.
No takes yet. Share an insight, caveat, or question.
kousar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from AMB Express